Single-arm P1/2 study | Glofitamab for relapsed or refractory diffuse Large B-Cell Lymphoma.

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4

— NEJM (@NEJM) December 11, 2022